Tiziana Life Sciences Ltd (NASDAQ:TLSA – Get Free Report) was the recipient of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 567,600 shares, a decline of 39.2% from the February 13th total of 934,300 shares. Based on an average trading volume of 955,300 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.8% of the company’s shares are sold short.
Hedge Funds Weigh In On Tiziana Life Sciences
Several hedge funds and other institutional investors have recently modified their holdings of TLSA. Sanctuary Advisors LLC purchased a new position in shares of Tiziana Life Sciences during the third quarter valued at about $864,000. Bison Wealth LLC purchased a new position in shares of Tiziana Life Sciences during the fourth quarter valued at about $30,000. Geode Capital Management LLC grew its holdings in Tiziana Life Sciences by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 245,722 shares of the company’s stock worth $171,000 after purchasing an additional 27,041 shares during the period. Finally, Zhang Financial LLC grew its holdings in Tiziana Life Sciences by 34.3% in the fourth quarter. Zhang Financial LLC now owns 93,187 shares of the company’s stock worth $65,000 after purchasing an additional 23,800 shares during the period.
Tiziana Life Sciences Stock Performance
TLSA stock opened at $1.57 on Friday. Tiziana Life Sciences has a 12-month low of $0.41 and a 12-month high of $1.91. The firm’s 50-day moving average price is $0.92 and its two-hundred day moving average price is $0.92.
Tiziana Life Sciences Company Profile
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Further Reading
- Five stocks we like better than Tiziana Life Sciences
- Insider Trades May Not Tell You What You Think
- How to Build the Ultimate Everything ETF Portfolio
- High Flyers: 3 Natural Gas Stocks for March 2022
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
